Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 22, 2027

Study Completion Date

January 22, 2027

Conditions
End Stage Renal DiseaseChronic Hemolysis
Interventions
DRUG

Medialipide 20% perfusion

Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.

DRUG

NaCl 0,9%

Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.

BIOLOGICAL

Blood sample

Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.

Trial Locations (1)

69003

Hopital Edouard Herriot, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER